GW433908 versus amprenavir in subjects with HIV-1 infection

$0M01FY2000RRNIH

University Of Texas Medical Br Galveston, Galveston TX

Investigators

Linked publications & trials

Paper 36513449 Paper 29256039 Paper 27918196 Paper 27412890 Paper 27160204 Paper 26032499 Paper 26011707 Paper 25468473 Paper 25308445 Paper 25132995 Paper 24439095 Paper 24045284 Paper 24008390 Paper 23588945 Paper 23406616 Paper 23299598 Paper 23283360 Paper 23242157 Paper 23202876 Paper 23123437 Paper 23055137 Paper 23044556 Paper 22985607 Paper 22968888 Paper 22968233 Paper 22486454 Paper 22464408 Paper 22440820 Paper 22136297 Paper 22108096 Paper 22022507 Paper 21949554 Paper 21880862 Paper 21865352 Paper 21626041 Paper 21624416 Paper 21572159 Paper 21528164 Paper 21507260 Paper 21440944 Paper 21429562 Paper 21305820 Paper 21280007 Paper 21273076 Paper 21263308 Paper 21173642 Paper 21128320 Paper 21050666 Paper 20981823 Paper 20874659 Paper 20851528 Paper 20813056 Paper 20735212 Paper 20724580 Paper 20711085 Paper 20578825 Paper 20576209 Paper 20547663 Paper 20535455 Paper 20484484 Paper 20410772 Paper 20409740 Paper 20391489 Paper 20338575 Paper 20308936 Paper 20184413 Paper 20112391 Paper 20070283 Paper 20051096 Paper 19965801 Paper 19950257 Paper 19948245 Paper 19919871 Paper 19918038 Paper 19888036 Paper 19859015 Paper 19828686 Paper 19793553 Paper 19790132 Paper 19699838 Paper 19616456 Paper 19592280 Paper 19588121 Paper 19566588 Paper 19541257 Paper 19536857 Paper 19522649 Paper 19501860 Paper 19476171 Paper 19476170 Paper 19476169 Paper 19476168 Paper 19476167 Paper 19476166 Paper 19476165 Paper 19476163 Paper 19454587 Paper 19419806 Paper 19390002 Paper 19370045

Abstract

This is a clinical research study of a new investigational anti-HIV medication, GW433908. GW433908 is a new form of amprenavir, a protease inhibitor, used to treat HIV infection. The current form of amprenavir requires patients to take a large number of capsules. GW433908 gets into the body more easily and reduces the number of pills patients have to take. The purpose of this study is to find the best dose of GW433908. This will be done by determining which dose of GW433908 gives similar blood concentrations to the marketed dose of amprenavir capsules. Eligible study subjects receive an experimental combination of abacavir, lamivudine and GW433908/amprenavir. Abacavir and lamivudine are from the nucleoside reverse transcriptase inhibitor (NRTI) class and amprenavir and GW433908 are from the protease inhibitor class of anti-HIV drugs. Both classes block enzymes that are necessary for the HIV virus to make copies of itself. With the exception of G@433908, the medications used in this study have been shown to decrease the amount of HIV virus in the blood and increase the CD4+ lymphocyte counts (white blood cells that fight off specific infections).

View original record on NIH RePORTER →